167 related articles for article (PubMed ID: 21057891)
21. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
[TBL] [Abstract][Full Text] [Related]
22. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
23. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
24. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
26. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.
Saleh HA; Jin B; Barnwell J; Alzohaili O
Diagn Pathol; 2010 Jan; 5():9. PubMed ID: 20181018
[TBL] [Abstract][Full Text] [Related]
27. Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.
Wallander M; Layfield LJ; Jarboe E; Emerson L; Liu T; Thaker H; Holden J; Tripp S
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):231-5. PubMed ID: 20042852
[TBL] [Abstract][Full Text] [Related]
28. Expression of Mcl-1 and Ki-67 in Papillary Thyroid Carcinomas.
Maia FF; Vassallo J; Pinto GA; Pavin EJ; Matos PS; Zantut-Wittmann DE
Exp Clin Endocrinol Diabetes; 2016 Apr; 124(4):209-14. PubMed ID: 27123780
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of distinguishing between follicular lesion and follicular neoplasm in thyroid fine-needle aspiration biopsy.
Williams MD; Suliburk JW; Staerkel GA; Busaidy NL; Clayman GL; Evans DB; Perrier ND
Ann Surg Oncol; 2009 Nov; 16(11):3146-53. PubMed ID: 19727961
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of DREAM gene mRNA levels in thyroid tumours.
Batista FA; Marcello MA; Martins MB; Peres KC; Cardoso UO; Silva ACDN; Bufalo NE; Soares FA; Silva MJD; Assumpção LV; Ward LS
Arch Endocrinol Metab; 2018; 62(2):205-211. PubMed ID: 29641740
[TBL] [Abstract][Full Text] [Related]
31. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction.
Bernet VJ; Anderson J; Vaishnav Y; Solomon B; Adair CF; Saji M; Burman KD; Burch HB; Ringel MD
J Clin Endocrinol Metab; 2002 Oct; 87(10):4792-6. PubMed ID: 12364475
[TBL] [Abstract][Full Text] [Related]
32. Impact of Reclassification on Thyroid Nodules with Architectural Atypia: From Non-Invasive Encapsulated Follicular Variant Papillary Thyroid Carcinomas to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Jeon MJ; Song DE; Jung CK; Kim WG; Kwon H; Lee YM; Sung TY; Yoon JH; Chung KW; Hong SJ; Baek JH; Lee JH; Kim TY; Shong YK; Kim WB
PLoS One; 2016; 11(12):e0167756. PubMed ID: 27936121
[TBL] [Abstract][Full Text] [Related]
33. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
34. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.
Shi X; Liu R; Basolo F; Giannini R; Shen X; Teng D; Guan H; Shan Z; Teng W; Musholt TJ; Al-Kuraya K; Fugazzola L; Colombo C; Kebebew E; Jarzab B; Czarniecka A; Bendlova B; Sykorova V; Sobrinho-Simões M; Soares P; Shong YK; Kim TY; Cheng S; Asa SL; Viola D; Elisei R; Yip L; Mian C; Vianello F; Wang Y; Zhao S; Oler G; Cerutti JM; Puxeddu E; Qu S; Wei Q; Xu H; O'Neill CJ; Sywak MS; Clifton-Bligh R; Lam AK; Riesco-Eizaguirre G; Santisteban P; Yu H; Tallini G; Holt EH; Vasko V; Xing M
J Clin Endocrinol Metab; 2016 Jan; 101(1):264-74. PubMed ID: 26529630
[TBL] [Abstract][Full Text] [Related]
35. The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology.
Bizzarro T; Martini M; Marrocco C; D'Amato D; Traini E; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM; Rossi ED
PLoS One; 2015; 10(7):e0132939. PubMed ID: 26186733
[TBL] [Abstract][Full Text] [Related]
36. Is BECLIN-1 Immunoreactivity More Effective than HBME-1 in Diagnosis of Papillary Thyroid Cancer?
Yeşil C; Kandemir O; Haksever H; Dabakoğlu T
Acta Chir Belg; 2015; 115(4):299-305. PubMed ID: 26324033
[TBL] [Abstract][Full Text] [Related]
37. [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma].
Hao Y; Jin C; Wang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 May; 27(9):457-61. PubMed ID: 23898609
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
[TBL] [Abstract][Full Text] [Related]
40. IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?
Lupo M; Guttler R; Geck Z; Tonozzi TR; Kammesheidt A; Braunstein GD
Endocr Pract; 2018 May; 24(5):453-459. PubMed ID: 29498908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
